Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Subcutaneous sumatriptan for refractory trigeminal neuralgia.

Akifumi Kanai1, Miwako Saito, Sumio Hoka

  • 1Department of Anesthesiology, Kitasato University School of Medicine, 1-15-1 Kitasato, Sagmihara 228-8555, Japan.

Headache
|April 29, 2006
PubMed
Summary

Sumatriptan, a 5-HT(1B/1D) receptor agonist, effectively reduced trigeminal neuralgia pain. This treatment provided prompt analgesia without serious adverse reactions in patients with refractory pain.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association Between Opioid Use and Sensory Perception in Patients with Cancer Pain: A Neurometric Study.

Pain medicine (Malden, Mass.)·2026
Same author

RE: Response to the readers' comments on our guidelines: Executive summary of the guidelines for prescribing opioid analgesics for chronic non-cancer pain (third edition) by the Japan Society of Pain Clinicians.

Journal of anesthesia·2026
Same author

Executive summary of the guideline for prescribing opioid analgesics for chronic non-cancer pain (third edition) by the Japan Society of Pain Clinicians.

Journal of anesthesia·2025
Same author

Anesthetic Management of an Adult Patient Post a Fontan Procedure in Laparoscopic Surgery: A Case Report.

Cureus·2024
Same author

Subcutaneous injection of lidocaine around ischemic ankle provides safe and effective foot analgesia in patients with critical limb ischemia.

Vascular·2024
Same author

Asenapine versus olanzapine for the treatment of nausea and vomiting in patients with cancer: A retrospective study.

Neuropsychopharmacology reports·2024

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Trigeminal neuralgia is often caused by mechanical compression of the trigeminal nerve root by an artery.
  • 5-HT(1B/1D) receptor agonists may alleviate neurogenic inflammation and vasodilation associated with trigeminal nerve irritation.

Purpose of the Study:

  • To evaluate the efficacy of sumatriptan, a 5-HT(1B/1D) receptor agonist, in managing paroxysmal pain characteristic of trigeminal neuralgia.

Main Methods:

  • A randomized, placebo-controlled crossover study involving 24 patients with treatment-refractory trigeminal neuralgia.
  • Patients received subcutaneous sumatriptan (3 mg) or placebo, followed by a crossover to the alternative treatment.
  • Pain intensity was measured using a Visual Analog Scale (VAS) before and 15 minutes after treatment.

Related Experiment Videos

Main Results:

  • Subcutaneous sumatriptan significantly reduced VAS scores from 8.3 to 2.4 cm, whereas placebo showed no significant effect.
  • Twenty out of twenty-four patients reported moderate to slight pain improvement with sumatriptan compared to only one with placebo.
  • The analgesic effect of sumatriptan lasted for a median of 7.9 hours.

Conclusions:

  • Subcutaneous sumatriptan offers prompt and effective pain relief for patients with trigeminal neuralgia refractory to other treatments.
  • The treatment was well-tolerated, with no serious adverse reactions reported.